
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1003 | 1003 | 1044 | 1028 | 1361 | 1396 |
Fund Return | 0.3% | 0.3% | 4.37% | 0.91% | 6.36% | 3.39% |
Place in category | 154 | 154 | 185 | 230 | 234 | 171 |
% in Category | 40 | 40 | 53 | 73 | 84 | 78 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GB0030932452 | 2.03B | 4.64 | 6.10 | 9.64 | ||
GB00B4WV2P70 | 2.03B | -1.40 | 2.64 | 9.20 | ||
MG Global Dividend Sterling A Acc | 2.01B | -3.63 | 7.24 | 9.60 | ||
MG Global Dividend Sterling I Acc | 2.01B | -3.53 | 7.67 | 10.22 | ||
MG Global Dividend Sterling A Inc | 2.01B | -3.63 | 7.24 | 9.61 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Artemis UK Select Fund I Acc | 1.86B | 0.90 | 12.67 | 9.00 | ||
Artemis UK Select Fund G Inc GBP | 738.31M | 5.79 | 13.25 | - | ||
Artemis UK Select Fund R Acc | 206.79M | 5.69 | 12.10 | 9.10 | ||
Artemis UK Select Fund I Inc GBP | 214.59M | 25.31 | 10.43 | 9.44 | ||
Fidelity Special Situations Fund W | 3.05B | 1.22 | 8.90 | 6.97 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
HSBC | GB0005405286 | 8.28 | 743.50 | +1.34% | |
AstraZeneca | GB0009895292 | 7.06 | 10,008.0 | -0.10% | |
Unilever | GB00B10RZP78 | 5.91 | 53.90 | +1.70% | |
London Stock Exchange | GB00B0SWJX34 | 5.31 | 11,165.0 | -0.31% | |
GSK plc | GB00BN7SWP63 | 4.15 | 1,294.00 | +1.49% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review